Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6161-6165

  Bhattarai, Bharat Raj ^a   Kafle, Bhooshan ^a   Hwang, Ji Sun ^b   Khadka, Deegendra ^a   Lee, Sun Myung ^b   Kang, Jae Seung ^b   Ham, Seung Wook ^c   Han, Inn Oc ^b   Park, Hwangseo ^d   Cho, Hyeongjin ^a  

^a Inha University   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Chung Ang University   (South Korea)

^d Sejong University   (South Korea)

Author keywords

Diabetes; Glitazones; Obesity; PTP1B inhibitor; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CHOLESTEROL; FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; GLUCOSE TOLERANCE; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERIZATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BINDING SITES; BLOOD GLUCOSE; CATALYTIC DOMAIN; COMPUTER SIMULATION; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MICE; PHENYL ETHERS; PPAR GAMMA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; THIAZOLIDINEDIONES;

EID: 71749083846     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.020     Document Type: Article

References (24)

1. Gale A.M. Lancet 357 (2001) 1870
2. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. J. Biol. Chem. 270 (1995) 12953
3. Yale J.F., Valiquett T.R., Ghazzi M.N., Owens-Grillo J.K., Whitcomb R.W., and Foyt H.L. Ann. Int. Med. 134 (2001) 737
4. Malamas M.S., Sredy J., Gunawan I., Mihan B., Sawicki D.R., Seestaller L., Sullivan D., and Flam B.R. J. Med. Chem. 43 (2000) 995
5. Maccari R., Ottanà R., Curinga C., Vigorita M.G., Rakowitz D., Steindl T., and Langer T. Bioorg. Med. Chem. 13 (2005) 2809
6. Maccari R., Paoli P., Ottanà R., Jacomelli M., Ciurleo R., Manao G., Steindl T., Langer T., Vigorita M.G., and Camici G. Bioorg. Med. Chem. 15 (2007) 5137
7. Combs A.P., Yue E.W., Bower M., Ala P.J., Wayland B., Douty B., Takvorian A., Polam P., Wasserman Z., Zhu W., Crawley M.L., Pruitt J., Sparks R., Glass B., Modi D., McLaughlin E., Bostrom L., Li M., Galya L., Blom K., Hillman M., Gonneville L., Reid B.G., Wei M., Becker-Pasha M., Klabe R., Huber R., Li Y., Hollis G., Burn T.C., Wynn R., Liu P., and Metcalf B. J. Med. Chem. 48 (2005) 6544
8. Ahn J.H., Kim S.J., Park W.S., Cho S.Y., Ha J.D., Kim S.S., Kang S.K., Jeong D.G., Jung S.-K., Lee S.-H., Kim H.M., Park S.K., Lee K.H., Lee C.W., Ryu S.E., and Choi J.-K. Bioorg. Med. Chem. Lett. 16 (2006) 2996
9. Park H., Jung S.-K., Jeong D.G., Ryu S.E., and Kim S.J. Bioorg. Med. Chem. Lett. 18 (2008) 2250
10. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.-C., Ramachandran C., Gresser M.J., Tremblay M.L., and Kennedy B.P. Science 283 (1999) 1544
11. You-Ten K.E., Muise E.S., Itie A., Michaliszyn E., Wagner J., Jothy S., Lapp W.S., and Tremblay M.L. J. Exp. Med. 186 (1997) 683
12. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., and Kahn B.B. Mol. Cell. Biol. 20 (2000) 5479
13. Rondinone C.M., Trevillyan J.M., Clampit J., Gum R.J., Berg C., Kroeger P., Frost L., Zinker B.A., Reilly R., Ulrich R., Butler M., Monia B.P., Jirousek M.R., and Waring J.F. Diabetes 51 (2002) 2405
14. Zinker B.A., Rondinone C.M., Trevillyan J.M., Gum R.J., Clampit J.E., Waring J.F., Xie N., Wilcox D., Jacobson P., Frost L., Kroeger P.E., Reilly R.M., Koterski S., Opgenorth T.J., Ulrich R.G., Crosby S., Butler M., Murray S.F., McKay R.A., Bhanot S., Monia B.P., and Jirousek M.R. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11357
15. Park, H.; Bhattarai, B. R.; Ham, S. W.; Cho, H. Eur. J. Med. Chem. 2009, 44, 3280.
16. Shrestha S., Bhattarai B.R., Kafle B., Lee K.-H., and Cho H. Bioorg. Med. Chem. 16 (2008) 8643
17. Shrestha S., Bhattarai B.R., Chang K.J., Lee K.-H., and Cho H. Bioorg. Med. Chem. Lett. 17 (2007) 2760
18. Cheng Y.-C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
19. 6): δ 167.40, 166.94, 155.69, 139.77, 134.34, 130.63, 130.54, 130.31, 128.20, 125.87, 124.61, 124.45, 121.89, 115.61, 113.02, 68.77.
20. Kanolt C.W. J. Am. Chem. Soc. 29 (1907) 1402
21. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
22. Liu G., Xin Z., Pei Z., Hajduk P.J., Abad-Zapatero C., Hutchins C.W., Zhao H., Lubben T.H., Ballaron S.J., Haasch D.L., Kaszubska W., Rondinone C.M., Trevillyan J.M., and Jirousek M.R. J. Med. Chem. 46 (2003) 4232
23. Mouse experiment: Twenty-four mice (4-wk old, 17-19 g, Japan SLC, Haruno Breeding branch, Hamamatsu, Japan) were individually housed and maintained in a 12 h dark-light cycle at 22 ± 2 °C. They were fed ad libitum. After acclimatization for 1 wk by feeding a LFD, the mice were divided into two groups; LFD (8 mice) and HFD (16 mice) groups. The LFD-fed lean control group was maintained on a LFD throughout the study. The HFD group of mice was provided with a HFD for the first 8 wk of the study for development of obesity/diabetes. Then, they were separated into two groups with the same mean body weight. Each group was then given a HFD or HFD plus 3e for 4 wk. Compound 3e was administered as a mixture with the food (2.0 g of 3e per kg of diet). For this, 3e (400 mg) was dissolved in 0.5 mL DMSO and homogenized with 1% aqueous solution of polyglycerol fatty acid ester (19.5 mL, Mitsubishi-kagaku foods, Tokyo, Japan). The homogeneous suspension was mixed thoroughly in a powder form of HFD (200 g) and kneaded into a dough. Body weight and food intake were recorded every third day during the drug feeding period. At the end of the drug feeding period, glucose tolerance tests were performed. After a 5 d recovery period on their own diet (the test group on HFD plus 3e), mice were fasted overnight and blood collected by cardiac puncture under secobarbital anesthesia. Liver, lung, kidney, and white adipose tissue were excised and weighed.
24. Mudaliar S., and Henry R.R. In: Porte D., Sherwin R.S., and Baron A. (Eds). Ellenberg & Rifkin's Diabetes Mellitus. 6th ed. Theory and Practice (2002), McGraw-Hill, New York 531-565